LPA and ischemic stroke: Potent Lp(a)‐lowering drugs—antisense oligonucleotides and small interfering RNAs—can reduce levels by 80%–95% in Phase 2 trials, and large Phase 3 studies (Lp(a)HORIZON for pelacarsen; OCEAN(a)‐Outcomes for olpasiran) are underway to determine whether lowering Lp(a) translates into fewer major events, including ischemic stroke [52].